Tagribo — Osimertinib 80 mg, 30 pcs, Techno Oncology

Tagribo — Osimertinib Tablets 80 mg, 30 Tablets

Product code: 521

8200₴ 8493₴ -3%
1
Active ingredient
Dosage form Tablets
Tablets per pack 30

Tagribo is an advanced targeted antineoplastic agent belonging to the tyrosine kinase inhibitor (TKI) class, indicated for the treatment of non-small cell lung cancer. The active pharmaceutical ingredient is osimertinib at a strength of 80 mg supplied as film-coated oral tablets (Osimertinib Tablets 80 mg). The product is manufactured by the Bangladeshi pharmaceutical company Techno Drugs Limited (Techno Oncology division).

Osimertinib is an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that highly selectively blocks both sensitizing EGFR mutations (exon 19 deletions and L858R substitution) and the T790M resistance mutation arising from first- and second-generation EGFR TKI therapy. The drug exhibits prominent blood-brain barrier penetration, ensuring highly effective control of metastatic lesions within the central nervous system.

Supplied in a package containing 30 tablets of 80 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of Tagribo 80 mg:

  • ✅ Third-Generation EGFR Inhibitor: High selectivity for sensitizing and T790M resistance mutations.
  • ✅ High CNS Activity: Excellent blood-brain barrier penetration for intracranial metastasis control.
  • ✅ Proven Clinical Efficacy: Significant prolongation of progression-free survival in both first-line and subsequent settings.
  • ✅ Convenient Oral Dosing: Taken orally once daily regardless of food intake.
  • ✅ Made by Techno Drugs (Bangladesh): High-quality, accessible generic alternative to the originator product (Tagrisso).

Tagribo is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Osimertinib (as osimertinib mesylate) — 80 mg.
  • Excipients: as listed in the manufacturer's package insert.

Packaging and Presentation: Film-coated tablets, 80 mg strength. Each package contains 30 tablets along with prescribing information. Labeled with TAGRIBO (Osimertinib Tablet) and Techno Oncology corporate graphics.

Pharmacodynamics:
Osimertinib is an irreversible inhibitor of mutant forms of the epidermal growth factor receptor (EGFR), including T790M, Ex19del, and L858R. It covalently binds to the cysteine residue in the EGFR kinase domain, suppressing phosphorylation and blocking tumor cell proliferation. The drug demonstrates significantly lower activity against wild-type EGFR, reducing adverse reactions in healthy tissues.

Pharmacokinetics:

  • Absorption: Following oral administration, osimertinib absorption is moderate; peak plasma concentration (Tmax) is achieved within approximately 6 hours. Food intake has no clinically significant effect on absorption.
  • Distribution: Human plasma protein binding is approximately 95%. High volume of distribution.
  • Metabolism: Extensively metabolized in the liver, primarily via cytochrome P450 enzymes (specifically CYP3A4 and CYP3A5).
  • Elimination: Excreted predominantly via feces (approx. 68%) and renally (approx. 14%). Terminal elimination half-life (T1/2) averages approximately 48 hours.

Tagribo is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Adjuvant therapy after tumor resection in patients with NSCLC harboring EGFR mutations (Ex19del or L858R); first-line treatment of locally advanced or metastatic NSCLC with activating EGFR mutations; and treatment of patients with locally advanced or metastatic NSCLC harboring the T790M mutation whose disease has progressed on or after prior EGFR TKI therapy.

Tagribo is administered orally once daily every day at approximately the same time.

Dosing Regimen:
The recommended standard therapeutic dose is 80 mg (one 80 mg tablet) once daily.

Administration Guidelines:
Tablets should be taken regardless of food intake with water. Tablets must be swallowed whole; do not break, crush, chew, or divide. If a dose is missed, take it as soon as possible unless the next dose is due within 12 hours. Do not double doses to make up for a missed dose.

Administration of Tagribo is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to osimertinib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction.
  • QT Interval Prolongation: Baseline prominent QTc interval prolongation.

Osimertinib is metabolized via CYP3A4 and CYP3A5 enzymes:

  • Strong CYP3A4 Inducers (rifampicin, phenytoin, carbamazepine, St. John's Wort): Significantly decrease osimertinib plasma concentrations and reduce antitumor efficacy. Avoid concurrent use.
  • Strong CYP3A4 Inhibitors: May elevate systemic osimertinib exposure, though dose adjustment is not always mandatory provided rigorous medical monitoring is maintained.
  • QT-Prolonging Drugs: Co-administration requires regular ECG monitoring.

Pregnancy:
Tagribo is contraindicated during pregnancy. Based on its mechanism of action, osimertinib may cause fetal harm and embryotoxicity. Females of reproductive potential must utilize effective reliable contraception during treatment and for at least 6 weeks following the final dose (males for 4 months).

Lactation:
Excretion of osimertinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Dermatologic Reactions: Rash, dry skin, pruritus, paronychia (nail fold inflammation), alopecia.
  • Gastrointestinal Tract: Diarrhea, stomatitis, nausea, decreased appetite, constipation.
  • General Disorders: Fatigue, asthenia, cough, arthralgia, myalgia.
  • Cardiovascular System: QT interval prolongation on ECG, left ventricular ejection fraction (LVEF) decrease.
  • Serious Effects: Interstitial lung disease (pneumonitis).

Symptoms:
Specific acute overdose symptoms of osimertinib are unestablished. Anticipated manifestations include exacerbated adverse reactions (dermatologic, gastrointestinal, cardiac toxicity).

Treatment:
No specific antidote exists. In case of overdose, withhold treatment and initiate supportive and symptomatic care under medical observation.

Storage Requirements for Tagribo 80 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify an authentic pack of Tagribo manufactured by Techno Drugs Limited (Bangladesh), check the following:

  • ✅ Branded packaging: An upright box with a teal-green upper part and a light lower part. Large white TAGRIBO lettering with Osimertinib Tablet beneath it, a purple ribbon on the right, 30 Tablets at the top and the Techno Oncology logo in the middle.
  • ✅ Factory markings: Batch number, manufacturing and expiry dates are clearly printed and match on the box and blisters.
  • ✅ Package insert: The manufacturer's prescribing information is enclosed in the pack.
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00